Sight Sciences Wins $34M Judgment Against Alcon in Patent Infringement Case
Event summary
- Sight Sciences secured a court order preserving a jury verdict of willful patent infringement by Alcon's Hydrus Microstent.
- The court awarded $34 million in damages plus ongoing 10% royalties on Hydrus revenue through November 2028.
- The final judgment is subject to appeal and potential USPTO reexamination proceedings.
- Sight Sciences expects to record a $5.4 million success fee to Cooley LLP.
The big picture
This legal victory reinforces Sight Sciences' position in the interventional glaucoma market, where patent protection is critical for maintaining competitive advantage. The ongoing royalties provide a revenue stream while the company continues to develop its pipeline of innovative eye care technologies. The case highlights the strategic importance of intellectual property in the medical device sector, particularly in high-stakes areas like glaucoma treatment.
What we're watching
- Appeal Risk
- Whether Alcon will successfully appeal the judgment and potentially reduce Sight Sciences' awarded damages.
- Royalty Impact
- The pace at which ongoing royalties from Hydrus sales will affect Sight Sciences' revenue through 2028.
- Pipeline Investment
- How the legal victory will influence Sight Sciences' ability to invest in its glaucoma treatment pipeline.
Related topics